Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: tcr: one small shareholder's view (again)

Fat -

I agree with everything you've stated.  The div. payments are also my biggest gripe - makes Patriot look like nothing but a shell.  A new company with a struggling shareprice has no business paying out dividends - IMO.  If it's not in the agreement, then there's no reason to pay them to Swartz. 

TCRs posts do make some valid points and I'm glad he's put them out here for Patriot insiders to read - because I hope it makes them re-think the dividend payments.  However, I think the horse is dead - we know how TCR's position and we know what his opposition thinks of him.  I don't think there's any need for this issue to keep perpetuating, digressing and turning into a bad soap opera. 

I recently made a "very small" investment in another OTC BB.  It's like a reoccurring nightmare - very same issues as Patriot.  Toxic / PIPE financer raping the retail shareholder.  Makes me wonder if it's business as usual for OTC BB stocks.  I can certainly understand why many experienced investors say stay the h*ll away from penny stocks.

Share
New Message
Please login to post a reply